title: Dabrafenib in metastatic melanoma: a monocentric 'real life' experience.
abstract: Dabrafenib is a potent BRAF-kinase inhibitor. Its activity was evaluated on 40 consecutive metastatic melanoma patients (pts) harboring the V600BRAF mutations. Dabrafenib was administered orally at the dosage of 150 mg b.i.d. daily. ORR was 82%, with 7% CR, 62% PR, 13% SD and 18% PD. The median PFS and OS were seven and 17 months, respectively (median follow-up: 8.5 months). Increased risk of progression was found in pts with elevated LDH, ECOG PS >1 and more than two metastatic sites. Grade 3-4 adverse events were recorded in 4 pts. In this retrospective analysis, Dabrafenib confirmed its role as the standard clinical option in metastatic melanoma pts.
authors.affiliation: Medical Oncology of Melanoma and Sarcoma Division, Istituto Europeo di Oncologia, via Ripamonti 435, Milan 2014, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Cocorocchio
authors.affiliation: Biostatistics Division, Istituto Europeo di Oncologia, via Ripamonti 435, Milan 2014, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Gandini
authors.affiliation: Medical Oncology of Melanoma and Sarcoma Division, Istituto Europeo di Oncologia, via Ripamonti 435, Milan 2014, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Alfieri
authors.affiliation: Medical Oncology of Melanoma and Sarcoma Division, Istituto Europeo di Oncologia, via Ripamonti 435, Milan 2014, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Battaglia
authors.affiliation: Sarcoma Unit, Istituto Europeo di Oncologia, via Ripamonti 435, Milan 2014, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Pennacchioli
authors.affiliation: Dermatoncological Surgery Division, Istituto Europeo di Oncologia, via Ripamonti 435, Milan 2014, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Tosti
authors.affiliation: Dermatoncological Surgery Division, Istituto Europeo di Oncologia, via Ripamonti 435, Milan 2014, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Spadola
authors.affiliation: Pathology Division, Istituto Europeo di Oncologia, via Ripamonti 435, Milan 2014, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Barberis
authors.affiliation: Medical Oncology of Melanoma and Sarcoma Division, Istituto Europeo di Oncologia, via Ripamonti 435, Milan 2014, Italy.
authors.forename: M Di
authors.initials: MD
authors.lastname: Leo
authors.affiliation: Medical Oncology of Melanoma and Sarcoma Division, Istituto Europeo di Oncologia, via Ripamonti 435, Milan 2014, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Riviello
authors.affiliation: Medical Oncology of Melanoma and Sarcoma Division, Istituto Europeo di Oncologia, via Ripamonti 435, Milan 2014, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Pala
authors.affiliation: Sarcoma Unit, Istituto Europeo di Oncologia, via Ripamonti 435, Milan 2014, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Intelisano
authors.affiliation: Medical Oncology of Melanoma and Sarcoma Division, Istituto Europeo di Oncologia, via Ripamonti 435, Milan 2014, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Martinoli
authors.affiliation: Medical Oncology of Melanoma and Sarcoma Division, Istituto Europeo di Oncologia, via Ripamonti 435, Milan 2014, Italy.
authors.forename: P F
authors.initials: PF
authors.lastname: Ferrucci
keywords: BRAF V600 mutation; Dabrafenib; metastatic melanoma; target therapy